drugset / Trial / NCT05561257

Vitamin C as add-on Therapy in Patients With Acute Herpes Zoster

NCT05561257 ↗

Phase 2 Terminated 12 enrolled Pascoe Pharmazeutische Praeparate GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy and tolerability of three different doses of Pascorbin® besides standard medication with placebo and the reduction of herpes zoster-associated clinical symptoms as an add-on therapy for patients suffering from acute herpes zoster in primary care

Timeline

Start
2020-07-20
Primary completion
2024-02-28
Completion
2024-02-28

Outcome

Outcome not reported

Stopped (Enrollment): “the necessary recruitment was no longer ensured and fundamental changes in the medical care of herpes zoster, which prevented the original research objectives and the feasibility of the study in the planned scope from being achieved”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 750 mg —
Subject Vitamin C Other / unclassified 7.5 g —
Subject Vitamin C Other / unclassified 15 g —

Indications